{"filings":[{"id":1417121,"accession_number":"0001493152-26-031945","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-07-02T21:00:35+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Raymond W. Cohen resigns from InspireMD board effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cohen resigned as Class III director and from Audit and Compensation Committees.","Resignation effective July 1, 2026, for personal considerations.","No disagreement with the Company, Board, or management.","Nominating and Corporate Governance Committee will seek a replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982478,"accession_number":"0001493152-26-028221","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-06-11T12:05:40+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD reports 100% acute device success, zero adverse events in CGUARDIANS II TCAR trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acute device success 100% (50/50 patients); no deaths, strokes, or MI at 30 days.","No stent thrombosis observed; complete stent patency in evaluable subjects.","PMA supplement under FDA review; potential approval H2 2026 for TCAR use.","CEO cites line-of-sight to full TCAR toolkit, addressing >35,000 annual US procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833609,"accession_number":"0001493152-26-027045","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-06-03T20:05:25+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"InspireMD shareholders approve authorized share increase to 250M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common shares from 150M to 250M (31,577,297 for, 3,009,107 against).","Re-elected directors Marvin Slosman, Raymond Cohen, Dan Dearen as Class 3 directors for three-year terms.","Ratified Kesselman & Kesselman (PwC) as independent auditor for fiscal 2026 (34,355,150 for, 244,248 against).","Quorum of 73.85% of outstanding shares (34,631,348 shares) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609356,"accession_number":"0001493152-26-025017","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-05-22T20:05:34+00:00","items":["5.02","9.01"],"status":"ready","headline":"Paul Stuka to retire as InspireMD Board Chair at 2027 Annual Meeting; not standing for reelection","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Stuka notified InspireMD on May 20, 2026, of his decision not to seek reelection as Class I director at the 2027 Annual Meeting.","Stuka currently serves as Board Chair, Compensation Chair, and member of Audit and Nominating & Corporate Governance committees.","He expects to continue in his roles until his term expires at the 2027 Annual Meeting; no disagreement with the company triggered the decision.","Nominating committee will begin succession planning to identify suitable board candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92832,"accession_number":"0001493152-26-021105","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.","GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.","Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.","FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.","Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3398000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92831,"accession_number":"0001493152-26-020891","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD recalls CGuard Prime 135 cm delivery system due to performance issues; withdraws FY2026 revenue guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary recall of CGuard Prime 135 cm delivery system in US; technical success not met. No safety issues for implanted stent.","FDA approval for original CGuard delivery system expected Q3 2026; delivery system used in over 70,000 cases worldwide.","Withdrawing prior full year 2026 revenue guidance due to temporary halt in US commercialization pending FDA approval.","FDA approved IDE for CGUARDIANS III pivotal study of SwitchGuard NPS for use with CGuard Prime 80 cm in TCAR procedures.","Q1 2026 global unit sales up 53% YoY; US unit sales up 34% QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92830,"accession_number":"0001493152-26-015127","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"InspireMD enters $75M ATM equity facility with BTIG; terminates prior Piper Sandler ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Equity Distribution Agreement with BTIG to sell up to $75M of common stock via ATM offering.","Terminated prior ATM with Piper Sandler; 1,361,519 shares had been sold under that facility.","Proceeds intended for R&D, sales/marketing, working capital, and general corporate purposes.","BTIG receives commission up to 3% of gross proceeds from sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103990,"accession_number":"0001493152-26-010791","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD reports Q4 revenue $3.1M (+62% YoY); guides FY2026 rev $13-15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.1M, up 62% YoY; U.S. rev $0.9M (sequential +74%)","Gross margin improved to 37.5% from 24.1% YoY; net loss $11.8M ($0.14/share)","Full year 2025 rev $9.0M (+28% YoY); net loss $48.8M","Cash and securities $54.2M at Dec 31, 2025 vs $34.6M year earlier","FY2026 revenue guidance $13-15M (45-65% growth); PMA-S submitted for TCAR indication"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103989,"accession_number":"0001493152-26-008894","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD dismisses COO Andrea Tommasoli effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrea Tommasoli, COO, given notice of dismissal on February 27, 2026.","Released from duties effective April 1, 2026; expected last day September 1, 2026.","Will receive base salary through 6-month notice period and benefits up to 12 months.","Severance of approximately €61,000 gross plus accrued untaken paid leave.","No replacement named; termination subject to French labor law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120263,"accession_number":"0001493152-25-028558","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD director Kathryn Arnold resigns; company awards ~$140k in accelerated equity and fees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathryn Arnold, Class III director, resigns effective Dec 31, 2025; no disagreement with company.","Compensation Committee accelerates unvested equity awards and extends option expiration by two years.","Company to pay three additional quarters of board and committee member fees.","Grant of ~$140k in common stock (75%) and options (25%) at Dec 30 closing fair market value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120262,"accession_number":"0001493152-25-020718","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD Q3 revenue record $2.5M (+39% YoY) as U.S. CGuard Prime launch gains traction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. revenue of $497k marks first commercial quarter for CGuard Prime carotid stent system.","Net loss $12.7M ($0.17/share) vs $7.9M ($0.16) a year ago; operating expenses up 57% on U.S. expansion.","Cash and marketable securities $63.4M at Sep 30, up from $34.6M at Dec 31, 2024, boosted by $58M July offering.","Over 100 U.S. carotid procedures completed; appointed Peter A. Soukas, M.D. as CMO and Dan Dearen to board.","Gross profit nearly doubled to $864k on favorable shift toward higher-margin U.S. sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":5830000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136849,"accession_number":"0001493152-25-013828","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD Appoints Dan Dearen to Board, Replacing Thomas Kester","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Kester resigned as Class III director effective Sept. 16, 2025; no disagreement cited.","Danny Lee Dearen Jr. appointed Class III director, Audit Committee chair, and Compensation Committee member.","Dearen received ~$180K equity grant (75% restricted stock, 25% stock options) vesting in one year.","Kester received accelerated vesting, extended option expiry, and ~$120K in stock/options as separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136845,"accession_number":"0001493152-25-012805","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K/A","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"InspireMD appoints Raymond Cohen to Audit and Compensation Committees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raymond W. Cohen appointed to Audit Committee and Compensation Committee on September 7, 2025.","Cohen had previously been appointed as a Class 3 director on July 31, 2025.","The Board made the committee assignments after the original 8-K filing; no other changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136848,"accession_number":"0001641172-25-022159","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.","Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.","Company raised $58M in gross proceeds from equity private placement and warrant exercise.","FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.","Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":3307000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136847,"accession_number":"0001641172-25-021675","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"InspireMD raises $58M via PIPE and warrant exercise; appoints Ray Cohen to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE gross proceeds $40.1M: 16.6M shares/pre-funded warrants at $2.42/share; led by OrbiMed and Marshall Wace.","Warrant exercise yields $17.9M: 12.9M Series I warrants exercised at $1.3827, triggered by FDA PMA of CGuard Prime.","Combined $58M to fund U.S. commercial launch of CGuard Prime; intended use includes sales/marketing, R&D, working capital.","Raymond W. Cohen appointed to Board (Cl. 3), effective Aug 1; former CEO of Axonics (sold to BSX for $3.7B), brings MedTech scaling expertise.","Directors Kathryn Arnold and Thomas Kester will not stand for reelection in 2026; expected resignations by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136846,"accession_number":"0001641172-25-018302","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD launches CGuard Prime carotid stent system in US after FDA PMA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. commercial launch of CGuard Prime carotid stent system after FDA PMA approval.","Device features dual-layer design with MicroNet mesh (20 µm PET) and SmartFit technology.","CEO Marvin Slosman notes double-digit market share in >30 countries; U.S. team assembled.","First commercial case performed by Dr. D. Chris Metzger at OhioHealth; Ballad Health involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154084,"accession_number":"0001641172-25-016293","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD receives FDA PMA approval for CGuard Prime carotid stent system; triggers $17.9M warrant tranche","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved CGuard Prime carotid stent system on June 23, 2025 for stroke prevention in carotid artery stenosis.","Pivotal C-GUARDIANS trial (316 patients) showed lowest 30-day (0.95%) and 1-year (1.93%) major adverse event rates.","FDA approval triggers second warrant tranche; gross proceeds expected $17.9M if exercised in full.","Proceeds to fund U.S. commercial launch, new regulatory pathways, and product development.","Over 65,000 CGuard Prime implants to date; investors include Marshall Wace, OrbiMed, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154083,"accession_number":"0001641172-25-014986","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD receives CE Mark approval for CGuard Prime EPS under EU MDR","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE Mark approval under European Medical Device Regulation (MDR) for CGuard Prime Embolic Prevention System.","Product designed with MicroNet mesh to reduce embolic events and prevent stroke.","Approval clears path for commercial launch in current CE-marked served markets.","Same platform intended for US launch later in 2025, subject to FDA approval.","CEO Marvin Slosman highlights regulatory milestone and next-generation platform advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154082,"accession_number":"0001641172-25-013433","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD appoints Michael Lawless as CFO, succeeding Craig Shore","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Lawless appointed CFO effective on/before June 30, 2025; succeeds Craig Shore who served ~15 years.","Base salary of $375,000 annually, plus performance bonus up to 50% of base salary.","Inducement grant: 212,000 stock options and 465,000 restricted shares, vesting over 3 years under NASDAQ Rule 5635(c)(4).","Employment agreement has 3-year initial term with automatic renewal; severance includes 6 months base salary (non-CIC) or 12 months (CIC).","Lawless previously CFO of Lifeward (LFWD) and held senior finance roles at Azenta, PerkinElmer, and Momenta Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154081,"accession_number":"0001641172-25-013427","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"InspireMD shareholders re-elect Berman and Ward, ratify auditors at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Berman and Ward re-elected as Class 2 directors: Berman 12,429,779 for, 248,915 withheld; Ward 12,447,235 for, 231,459 withheld; 7,800,113 broker non-votes each.","Ratification of Kesselman & Kesselman as FY2025 independent auditor approved: 20,308,180 for, 164,980 against, 5,647 abstain.","Annual meeting quorum of 66.84% achieved with 20,478,807 shares present out of 30,635,356 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154080,"accession_number":"0001641172-25-009364","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q1 net loss widens to $0.22/sh; FDA approval of CGuard Prime expected Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.529M (+1.2% YoY); net loss $11.166M ($0.22/sh) vs $7.032M loss ($0.21/sh) in Q1 2024.","Operating expenses rose 52.5% to $11.752M on U.S. sales force build and CGuard Prime launch preparation.","Cash and securities $26.086M at March 31, down from $34.637M at Dec 31, 2024.","FDA PMA for CGuard Prime carotid stent system anticipated in Q3 2025; commercial team in place."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1529000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172698,"accession_number":"0001493152-25-009936","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q4 net loss widens to $9.2M; revenue up 11%; FDA approval for CGuard Prime expected H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue rose 10.7% YoY to $1.95M; gross profit fell 7.1% to $469K as COGS grew faster.","Net loss widened to $9.17M ($0.19/sh) from $5.41M ($0.16/sh); operating expenses surged 56% to $9.84M.","Full-year 2024 revenue $7.01M (+13% YoY); net loss $32.0M ($0.76/sh) vs $19.9M ($0.82/sh).","Cash and marketable securities $34.6M at Dec 31, 2024, down from $39.0M a year earlier.","Submitted PMA to FDA for CGuard Prime; enrolled first patients in CGUARDIANS II TCAR study; expects US approval H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189713,"accession_number":"0001493152-24-049727","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD CFO Craig Shore to retire; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Shore, CFO for 15 years, will retire after successor appointed; he will assist transition.","Company initiated search for next CFO; Shore remains in role until successor is named.","Severance amendment provides 200% of base salary plus 24 months benefits if terminated without cause.","CEO cites potential U.S. FDA approval in H1 2025 as reason for CFO transition now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189712,"accession_number":"0001493152-24-049199","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD enrolls first patient in CGUARDIANS II pivotal TCAR study for CGuard Prime","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled by Dr. Patrick Muck at Good Samaritan Hospital (TriHealth, Cincinnati).","Prospective, single-arm study: 50+ evaluable patients; acute device/technical success endpoints.","CEO targets FDA approval for CGuard Prime CAS indication in H1 2025; TCAR market ~30,000 procedures/year.","Over 60,000 CGuard devices sold globally; MicroNet mesh cited for protective outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189711,"accession_number":"0001493152-24-047617","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD appoints medtech executive Scott R. Ward to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott R. Ward, former CEO of Cardiovascular Systems and Abbott leader, joins as Class II director.","Ward received options for 16,647 shares and 43,548 restricted stock, vesting on one-year anniversary.","Management highlights Ward's cardiovascular expertise ahead of potential U.S. approval of CGuard Prime.","Ward has over 40 years healthcare experience, including 30 years at Medtronic in senior leadership roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189710,"accession_number":"0001493152-24-044599","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"InspireMD Q3 revenue record $1.81M (+16.3% YoY); net loss $7.89M; submits PMA to FDA for CGuard Prime","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue record $1.81M, up 16.3% YoY; gross margin 22.9% down from 28.1% due to higher costs.","Net loss $7.89M ($0.16/share) vs $5.18M ($0.15/share) in Q3 2023; operating expenses rose 46% to $8.88M.","Submitted PMA to FDA for CGuard Prime carotid stent; targets U.S. approval in H1 2025.","IDE approved for CGUARDIANS II pivotal study of CGuard Prime for TCAR procedures.","Cash and marketable securities $40.4M at Sept 30, 2024; new Miami HQ to support U.S. launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":5060000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189709,"accession_number":"0001493152-24-041036","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"InspireMD establishes Miami global HQ; anticipates U.S. launch of CGuard Prime in H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New global headquarters in Miami, Florida to support anticipated U.S. launch of CGuard Prime carotid stent system.","Company expects potential FDA approval and U.S. launch in first half of 2025.","Lease for 10,782 sq ft office space with 64-month term; $500,000 security deposit.","Building commercial teams and infrastructure to support U.S. market.","Submitted final module of PMA to FDA on September 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189708,"accession_number":"0001493152-24-039640","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"FDA approves IDE for InspireMD's CGUARDIANS II pivotal study of CGuard Prime 80cm stent system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IDE application for CGUARDIANS II pivotal study of CGuard Prime 80cm Carotid Stent System during TCAR procedures.","Study intended to facilitate approval of CGuard Prime for TCAR indication; U.S. commercial sales after approval.","Co-principal investigators: Patrick Geraghty, M.D. (Washington Univ.) and Patrick Muck, M.D. (Good Samaritan Hospital).","Company also advancing development of next-generation TCAR neuroprotection system, SwitchGuard NPS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189707,"accession_number":"0001493152-24-039017","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD adopts 2024 Inducement Plan, reserves 2,200,000 shares for new employee awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation committee approved 2024 Inducement Plan on September 30, 2024.","Plan reserves 2,200,000 shares of common stock for issuance as inducement grants.","Awards limited to new employees not previously employed by the company, per Nasdaq Rule 5635(c)(4).","Plan terms are substantially similar to the 2021 Equity Incentive Plan; no incentive stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206218,"accession_number":"0001493152-24-036293","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD submits PMA to FDA for CGuard Prime carotid stent; U.S. launch targeted H1 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PMA submission on Sept 16, 2024, seeks FDA marketing approval for CGuard Prime carotid stent system.","Application based on C-GUARDIANS pivotal trial showing 1.95% primary endpoint major adverse event rate through 12 months.","Trial enrolled 316 patients across 24 U.S. and European sites; lowest event rate reported for any carotid stent pivotal trial.","U.S. commercial launch anticipated in first half of 2025, subject to FDA approval.","CEO Marvin Slosman cites best-in-class clinical outcomes and building U.S. commercial infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206217,"accession_number":"0001493152-24-030372","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q2 2024 revenue up 5.4% to $1.74M; net loss widens; positive CGuard trial data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $1.74M (+5.4% YoY); gross margin fell to 19.0% from 29.8% on higher costs.","Net loss $7.9M ($0.22/share) vs $5.1M ($0.24) YoY; operating expenses up 48% to $8.6M.","CGuard stent sales 2,969 units; one-year C-GUARDIANS trial primary endpoint rate 1.95% (lowest ever).","Raised $17.9M gross from full exercise of Series H warrants; cash & equivalents $47.2M at June 30.","Intends to submit PMA application to FDA this quarter; plans CGUARDIANS II TCAR trial in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":3250000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206216,"accession_number":"0001493152-24-025714","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD completes full exercise of Series H warrants for $17.9M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $17.9M; net proceeds $16.9M after fees.","Warrants exercised after positive one-year C-GUARDIANS trial follow-up.","Proceeds to fund CGuard Prime CAS delivery system and SwitchGuard TCAR NPS.","Participants include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and Board members.","First of four milestone-based tranches from May 2023 private placement of up to $113.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223276,"accession_number":"0001493152-24-023685","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD posts updated investor presentation; content unavailable in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an investor presentation dated June 2024 under Item 7.01 on June 13, 2024.","Presentation was posted on company website and included as Exhibit 99.1 to the 8-K.","No specific financial data, guidance, or operational updates are provided in the filing body.","Investors should access the presentation directly for any potential material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223275,"accession_number":"0001493152-24-023546","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"InspireMD Announces Results of 2024 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Paul Stuka and Gary Rubin as Class 1 directors with 12,361,205 and 12,377,887 votes for, respectively.","Nonbinding advisory vote on named executive officer compensation approved: 9,539,687 for, 1,194,733 against, 1,898,288 abstain.","Advisory vote on frequency of future say-on-pay: every three years received 5,993,405 votes; company will hold votes every three years.","Ratification of Kesselman & Kesselman (PwC) as independent auditor for 2024 passed: 17,544,555 for, 134,905 against, 36,575 abstain.","Quorum of 75% was present at the meeting, with 17,716,035 of 23,401,435 shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223274,"accession_number":"0001493152-24-022222","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"InspireMD enters $17M at-the-market equity distribution agreement with Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM allows sale of up to $17M of common stock; Piper Sandler receives 3.0% commission on gross proceeds.","Company terminates prior AGP Sales Agreement (up to $8.313M); no shares were ever sold under that ATM.","Proceeds to be used for operations, R&D, sales/marketing, and working capital.","Offering conducted via prospectus supplement to existing effective S-3 registration statement (File No. 333-265409)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223273,"accession_number":"0001493152-24-021463","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD C-GUARDIANS trial shows 1.95% primary endpoint event rate; PMA filing planned H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint event rate of 1.95% through 12 months post-procedure, lowest reported for any carotid stent pivotal trial.","316 patients enrolled at 24 US/EU sites from July 2021 to June 2023; high-risk carotid endarterectomy patients.","Data to support PMA application to FDA in H2 2024; US launch of CGuard Prime anticipated H1 2025 if approved.","Results presented at LINC 2024 on May 28; investigator confirmed neuroprotective potential of MicroNet technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223272,"accession_number":"0001493152-24-019080","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q1 revenue up 22% to $1.51M; net loss widens to $7.0M ($0.21/sh)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.51M (+22% YoY); stent units sold 2,553 (+25.6% YoY).","Net loss $7.03M ($0.21/sh) vs $4.26M ($0.53/sh) in Q1 2023; operating expenses $7.71M (+62%).","Gross margin fell to 19.4% from 30.1% due to higher training costs.","Cash $34.0M; one-year C-GUARDIANS results to be presented at LINC 2024.","CE Mark recertified under MDR; Pete Ligotti appointed EVP/GM North America."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1511000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223271,"accession_number":"0001493152-24-012648","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD amends CEO and CFO employment agreements to enhance change-in-control severance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Marvin Slosman receives 24-month base salary severance plus 2x performance bonus on change-in-control termination.","CFO Craig Shore receives 12-month base salary severance plus 1x annual bonus on change-in-control termination.","Both executives get extended option exercise periods (CEO 2 years, CFO 1 year) and up to 24-month (CEO) or 12-month (CFO) benefit continuation.","Amendments effective April 1, 2024; triggered by termination within 3 months before or 12 months after a change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242758,"accession_number":"0001493152-24-011233","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD's C-GUARDIANS 12-month abstract accepted for LINC 2024; prior 30-day DSMI 0.95%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract of 12-month outcomes from C-GUARDIANS trial (316 patients, 24 sites) accepted for LINC 2024 (May 28-31, Leipzig).","Previously reported 30-day DSMI rate of 0.95% (ITT) and 0.63% (per-protocol).","Positive 12-month data could support PMA submission later in 2024 and potential U.S. launch of CGuard Prime in H1 2025.","Trial evaluates CGuard Carotid Stent System for carotid artery stenosis; primary endpoint includes death, stroke, MI through 365 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242757,"accession_number":"0001493152-24-008941","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q4 revenue jumps 71.6% to $1.76M; net loss $0.16 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 CGuard EPS revenue of $1.76M, up 71.6% YoY; 3,107 stents sold (+74.5%).","C-GUARDIANS trial showed 0.95% DSMI rate at 30 days; PMA submission expected mid-2024.","CE Mark recertified under EU MDR, enabling new product development pathway.","CMS expanded CAS coverage to asymptomatic and standard-risk patients, widening U.S. market.","Cash and equivalents $39.0M at Dec 31, 2023, up from $17.8M a year earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242756,"accession_number":"0001493152-24-004411","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD Receives CE Mark Recertification Under EU MDR for CGuard Stent System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE Mark recertification under EU's new Medical Device Regulation (MDR) obtained.","CGuard EPS can continue to be marketed in existing EU territories.","U.S. C-GUARDIANS IDE trial primary endpoint results expected mid-2024.","Final module of PMA submission to FDA planned for second half of 2024.","Potential U.S. approval of CGuard Prime EPS stent system in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260141,"accession_number":"0001493152-23-045512","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD receives U.S. patent for SwitchGuard NPS; IDE submission planned for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. Patent No. 11,844,893 issued for 'Shunts with Blood Flow Indicators' covering SwitchGuard NPS.","SwitchGuard NPS designed to reverse blood flow and filter embolic debris during carotid stenting.","Company expects to submit IDE to FDA in 2024 to initiate clinical trial for SwitchGuard NPS with CGuard Prime.","CMS expanded coverage for carotid artery stenting to asymptomatic and standard risk patients in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260140,"accession_number":"0001493152-23-042709","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD announces EFS agreement with Jacobs Institute for CGuard EPS in tandem lesion stroke patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jacobs Institute to execute an Early Feasibility Study (EFS) of CGuard EPS for acute stroke with tandem lesions.","EFS to enroll 15 patients across 3 U.S. sites; no FDA-approved stents currently exist for this indication.","CGuard EPS features MicroNet mesh covering for embolic protection, low metal surface area to reduce thrombotic risk.","CEO Marvin Slosman states tandem lesion indication is a critical component of long-term growth strategy.","Dr. Siddiqui notes ~20% of acute strokes are tandem, and stenting in conjunction with thrombectomy may be superior."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260139,"accession_number":"0001493152-23-039434","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q3 revenue +8.8% to $1.56M; CMS expands CAS coverage; trial results positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.556M (+8.8% YoY); gross margin 28.1% (vs 25.6% Q3 2022).","Net loss $5.178M ($0.15/diluted share) vs $4.529M ($0.58) in Q3 2022; cash $43.0M.","Positive 30-day C-GUARDIANS IDE results: major adverse events (death/stroke/MI) rate 0.95% at VIVA23.","CMS final NCD expanded CAS coverage to asymptomatic & standard risk patients, broadening addressable market.","Leadership additions: Patrick Verta EVP Clinical, Cheryl Tal VP QA/RA; Shane Gleason promoted to CCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4444000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260138,"accession_number":"0001493152-23-038979","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD reports positive 30-day C-GUARDIANS trial results: 0.95% DSMI rate in 316 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMI (death, stroke, MI) rate of 0.95% through 30 days post-procedure in 316 high-risk carotid artery stenosis patients.","Trial enrolled from July 2021 to June 2023 across 24 US and EU sites; single-arm, prospective IDE study.","Primary endpoint composite includes 30-day DSMI plus ipsilateral stroke from day 31 to 365; success if upper 95% CI < 11.6%.","Primary endpoint results expected H2 2024; potential FDA premarket approval application targeted for H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260137,"accession_number":"0001493152-23-036981","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS expands carotid stenting coverage to asymptomatic/standard-risk patients; InspireMD supports","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS final NCD extends CAS coverage to asymptomatic and standard-risk patients, expanding addressable market.","InspireMD advancing CAS and TCAR programs in U.S. and E.U. using CGuard EPS stent system.","C-GUARDIANS IDE trial completed enrollment; 30-day safety results at VIVA Nov 1, 2023; PMA filing anticipated H2 2024.","CGuard EPS stent studied in nine clinical trials with >1,850 patients and over 40,000 real-world procedures.","CEO says CMS decision will accelerate shift from open surgery to endovascular 'stent first' approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260136,"accession_number":"0001493152-23-036502","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD reappoints Craig Shore as CFO; Kohen returns to VP role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Shore reappointed as CFO, Secretary and Treasurer effective October 5, 2023.","Amir Kohen, interim CFO since July 21, 2023, returns to VP of Finance and HR role.","Kohen had served as interim CFO following Mr. Shore's prior departure in July."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277432,"accession_number":"0001493152-23-032486","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"InspireMD shareholders approve officer liability limitation and private placement change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Marvin Slosman, Thomas J. Kester, and Kathryn Arnold as Class 3 directors.","Approved amendment to certificate of incorporation to limit officer personal liability for monetary damages.","Approved potential issuance of shares in private placement that triggers Nasdaq change-of-control rule.","Ratified Kesselman & Kesselman (PwC) as independent auditor for fiscal 2023.","Amendment filed with Delaware Secretary of State on September 13, 2023, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277431,"accession_number":"0001493152-23-030726","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD: C-Guardians 30-day results abstract accepted for VIVA23 presentation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract of 30-day results from C-Guardians IDE trial accepted as late-breaking presentation at VIVA23 (Oct 30-Nov 2, Las Vegas) on Nov 1, 2023, by Dr. Chris Metzger.","Trial enrolled 316 patients across 25 U.S. and European sites; includes symptomatic and asymptomatic carotid artery stenosis patients.","Primary endpoint: composite of death, all stroke, MI through 30 days and ipsilateral stroke 31-365 days; performance goal: upper bound 95% CI <11.6%.","CEO expects one-year data in H2 2024; if positive, may support PMA and potential U.S. launch of CGuard Prime EPS in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277430,"accession_number":"0001493152-23-027101","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD reports Q2 revenue up 9.6% to $1.65M; secures up to $113.6M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Closed transformational private placement: $42.2M upfront, up to $71.4M additional on milestone warrants.","Completed enrollment in C-Guardians IDE trial; anticipates PMA submission in H2 2024.","Q2 CGuard EPS revenue $1.65M (+9.6% YoY); units sold 2,804 (+7.8% YoY).","Net loss $5.08M ($0.24 per share) vs $4.64M ($0.59) in Q2 2022.","Cash $47M as of June 30, up from $17.8M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2888000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41920869.891984075,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-08T23:59:59+00:00|277430"}